SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Singleton who wrote (5323)7/14/1998 9:00:00 PM
From: Thomas M.  Read Replies (2) of 9719
 
My 2&#162: Neurogen

Say, for example, that it's anti-anxiety drug works out. Valium minus the side effects, could become a blockbuster drug in the hands of PFE's marketers. Then, if the obesity drug comes up with a great looking trial, the stock could really take off. NRGN is down partly because of the perception that they can't get a drug into Phase II. However, I think their partner, PFE, is known for doing exhaustive early trials. A ten-bagger would put NRGN at a $2 billion market cap, not out of the question given the markets it is addressing and the partners it has.

Tom
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News